Previous 10 | Next 10 |
home / stock / wllw:cc / wllw:cc news
WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING Canada NewsWire CALGARY, AB , Oct. 10, 2023 /CNW/ - Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF)...
--News Direct-- Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to announce a significant collaboration agreement between Willow Biosciences and Suanfarma. The partnership is focused on optimizing cell line productivity for manufacturing a high-volume anti-in...
WILLOW AND SUANFARMA ANNOUNCE COLLABORATION ON DEVELOPMENT OF LARGE VOLUME ANTI-INFECTIVE API THROUGH PRECISION FERMENTATION Canada NewsWire SUNNYVALE, Calif. , Oct. 3, 2023 /CNW/ - Willow Biosciences Inc., ( "Willow" ) (TSX: WLLW) (OTCQB: CANSF) and SUANFARM...
--News Direct-- Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to announce some significant developments within the company. Willow Bioscience specializes in the production of ursodeoxycholic acid (UDCA), a vital pharmaceutical ingredient with extensive appl...
WILLOW BIOSCIENCES ANNOUNCES COMPANY INSIDER LED CONVERTIBLE DEBENTURE FINANCING Canada NewsWire /NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES . ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITI...
WILLOW ANNOUNCES SUCCESSFUL COMPLETION OF R&D PROGRAM ON COST-EFFECTIVE, SUSTAINABLY PRODUCED UDCA WILLOW ANNOUNCES SUCCESSFUL COMPLETION OF R&D PROGRAM ON COST-EFFECTIVE, SUSTAINABLY PRODUCED UDCA Canada NewsWire Company's BioOxi™ Platform solves for select...
--News Direct-- Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to announce a groundbreaking development in the pharmaceutical industry. Savile shared the company's achievement in creating a cost-effective process for producing corticosteroids using their inn...
WILLOW ANNOUNCES FILING OF PATENT APPLICATION FOR PROCESS TO PRODUCE CORTICOSTEROIDS AT SIGNFICANTLY REDUCED COST Canada NewsWire Company's BioOxi™-based process reduces number of steps and associated costs of corticosteroids manufacturing by up to two-thirds ...
--News Direct-- Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share news the company has embarked on a major strategic shift, focusing its commercial efforts on the BioOxi platform. To assist in this transition, Willow Biosciences has engaged an advisor to e...
WILLOW BIOSCIENCES ANNOUNCES COMMERCIAL TRANSITION AND FOCUS ON BIOOXI PLATFORM Canada NewsWire Announces commercial focus on BioOxi TM bio-oxidation platform as part of targeted alignment on nearer-term and larger revenue opportunities Reduces number of board memb...
News, Short Squeeze, Breakout and More Instantly...
Willow Biosciences Inc. Company Name:
WLLW:CC Stock Symbol:
TSXC Market:
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Canada NewsWire Company continues to advance its corticosteroid production platform and anticipates signing a large strategic partnership in Q2 2024 Signed two new program agr...
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF Canada NewsWire Completed the reorganization of the Company during 2023 with all lab operations now located in the Sunnyvale, California Record...
WILLOW BIOSCIENCES ANNOUNCES SECOND STRATEGIC INVESTMENT FROM KALSEC Canada NewsWire CALGARY, AB , Feb. 29, 2024 /CNW/ - Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology c...